Northrop Grumman Corporation
NOC
$473.46
-2.00%
Northrop Grumman Corporation is a diversified defense and aerospace prime contractor operating across four reporting segments — Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems — producing platforms such as the B-21 Raider stealth bomber, Global Hawk autonomous aircraft, missile defense interceptors, radar and electronic warfare suites, and satellites and rocket motors for national security customers. As one of the five major U.S. defense primes, Northrop occupies a distinct competitive position anchored in long-cycle, cost-plus and fixed-price franchise programs (notably the B-21 and Sentinel ICBM) that create multi-decade revenue visibility but also concentrate execution risk in a handful of mega-programs. The current investor narrative is dominated by a sharp divergence between geopolitical tailwinds — escalating U.S.-Iran tensions, the Trump administration's JATM missile procurement deal, and the Pentagon's aggressive pivot toward AI-enabled autonomous systems — and a stock that has de-rated dramatically, with shares down roughly 21% over the past year and trading near 52-week lows despite a record $95 billion-plus backlog environment. Debate centers on whether the selloff reflects transient program charges and working-capital swings (Q1 2026 free cash flow was deeply negative) or a structural margin and cash-conversion problem, particularly as the B-21 transitions toward low-rate production and the company absorbs supply-chain pressures including rare-earth magnet dependencies.…
NOC
Northrop Grumman Corporation
$473.46
Related headlines
Investment Opinion: Should I buy NOC Today?
Rating: Hold. The core thesis is that NOC is a high-quality defense franchise trading at a discounted valuation (forward PE 15.7x) with 34% upside to analyst targets, but near-term cash flow and margin headwinds warrant caution until execution improves. The analyst consensus rating of Buy (2.0) and average target of $639.23 anchor the view that the selloff is overdone, yet the stock's -36% relative underperformance over one year suggests structural concerns are not fully resolved. Supporting evidence includes: (1) forward PE of 15.7x versus trailing 19.6x, implying expected earnings growth; (2) revenue growth of 5.07% year-over-year in Q2 2026, with EPS rising to $7.70 from $6.16 in Q1; (3) ROE of 25.1% and a 1.58% dividend yield with a sustainable 30.9% payout ratio; and (4) free cash flow TTM of $3.65B, which, while modest, covers the dividend. The biggest risks are margin compression (gross margin down to 19.5% from 21.4%), negative free cash flow in Q1 2026, and a debt-to-equity ratio of 1.18x. The rating would upgrade to Buy if gross margins stabilize above 20% and free cash flow turns positive for two consecutive quarters, or if the stock drops below $450 (implied forward PE ~12x). It would downgrade to Sell if revenue growth decelerates below 3% or if a major program charge exceeds $500M. Relative to its own history and peers, NOC appears undervalued on a forward PE basis, but the PEG ratio of 7.41 suggests the market is pricing in low growth expectations.
Sign up to view all
NOC 12-Month Price Forecast
NOC presents a classic value trap versus turnaround debate. The valuation is undeniably attractive at 15.7x forward earnings with a 1.58% dividend yield, and analyst targets suggest significant upside. However, the company's negative free cash flow, margin compression, and high leverage (D/E 1.18x) are real concerns that could persist. The negative beta of -0.11 means the stock won't hedge market downturns, and the rare-earth supply chain issue adds a structural overhang. I would upgrade to bullish if Q3 2026 shows positive free cash flow and gross margin stabilization above 19.5%. I would downgrade to bearish if free cash flow remains negative or if a major program charge is announced. The risk/reward is balanced, favoring a Hold until execution improves.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Northrop Grumman Corporation's 12-month outlook, with a consensus price target around $634.04 and implied upside of +33.9% versus the current price.
Average Target
$634.04
0 analysts
Implied Upside
+33.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$525 - $815
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: NOC Investment Factors
The bear case currently has stronger evidence, driven by NOC's -36% relative underperformance versus the S&P 500 over one year, margin compression, and negative free cash flow. However, the bull case rests on a compelling valuation disconnect: forward PE of 15.7x and analyst targets implying 34% upside suggest the market has over-punished the stock for transient issues. The single most important tension is whether the B-21's transition to low-rate production will restore cash conversion and margins, or whether structural cost pressures will persist. If Q3 2026 earnings show improving free cash flow and stable gross margins above 19%, the bull case could rapidly gain traction. Conversely, another quarter of negative FCF or a program charge would validate the bear thesis and likely push shares toward the 52-week low of $470.06.
Bullish
- Analyst consensus sees 34% upside: 22 analysts rate NOC a Buy (recommendation_mean 2.0) with an average target price of $639.23, implying 33.7% upside from the current $478.00. Even the lowest analyst target of $525.00 sits 9.8% above the current price, suggesting the selloff has overshot fundamental value.
- Forward PE of 15.7x is historically cheap: NOC trades at a forward PE of 15.70x versus a trailing PE of 19.57x, reflecting expected EPS growth to $37.82 (analyst average). For a defense prime with a $95B+ backlog, this multiple is well below the broader market and offers a margin of safety.
- Revenue growth accelerating sequentially: Q2 2026 revenue of $10.88B grew 5.07% year-over-year, and EPS jumped to $7.70 from $6.16 in Q1 2026. The sequential EPS improvement of 25% indicates operational momentum despite the stock's 21% one-year decline.
- Geopolitical tailwinds and JATM deal: Escalating U.S.-Iran tensions and the Trump administration's JATM missile procurement deal directly benefit Northrop's Defense Systems segment. The Pentagon's AI pivot toward autonomous systems also aligns with Northrop's Global Hawk and B-21 franchises.
Bearish
- Severe relative underperformance vs. market: NOC has declined 20.99% over the past year while the S&P 500 gained 15.01%, a relative strength gap of -36.0 percentage points. Over six months, the underperformance widens to -49.3 points, signaling deep institutional selling.
- Margin compression and negative FCF: Gross margin fell to 19.5% in Q2 2026 from 21.4% in Q2 2025, and operating margin is just 10.2%. Q1 2026 free cash flow was deeply negative, raising concerns about cash conversion as the B-21 transitions to low-rate production.
- Elevated leverage and PEG ratio: Debt-to-equity stands at 1.18x with a current ratio of only 1.09, leaving limited liquidity buffer. The PEG ratio of 7.41 suggests the stock is expensive relative to its growth rate, and interest expense of $161M per quarter weighs on net income.
- Beta of -0.11 offers no market hedge: NOC's negative beta means it has historically moved inversely to the market, failing to provide defense as a safe-haven asset. In a risk-off environment, this correlation breakdown can amplify portfolio volatility rather than dampen it.
NOC Technical Analysis
Beta
-0.11
-0.11x market volatility
Max Drawdown
-38.4%
Largest decline past year
52-Week Range
$470-$774
Price range past year
Annual Return
-23.8%
Cumulative gain past year
| Period | NOC Return | S&P 500 |
|---|---|---|
| 1m | -8.1% | +0.9% |
| 3m | -11.0% | +3.4% |
| 6m | -29.7% | +14.4% |
| 1y | -23.8% | +16.2% |
| ytd | -19.2% | +14.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
NOC Fundamental Analysis
Quarterly Revenue
$10.9B
2026-06
Revenue YoY Growth
+5.1%
YoY Comparison
Gross Margin
19.5%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is NOC Overvalued?
PE
19.6x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 10x~21x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. NOC carries a debt-to-equity ratio of 1.18x and a current ratio of just 1.09, indicating tight liquidity. Q1 2026 free cash flow was deeply negative, and trailing free cash flow of $3.65B is modest relative to $10.9B in quarterly revenue. Gross margin has compressed to 19.5% from 21.4% a year ago, and the B-21 program's shift to low-rate production could pressure margins further if cost overruns materialize. Additionally, revenue is concentrated in a few mega-programs, making the company vulnerable to any single program's delays or budget cuts. Market and competitive risks are equally concerning. NOC trades at a forward PE of 15.7x, which is not expensive in absolute terms, but the PEG ratio of 7.41 signals that growth is not keeping pace with the multiple. The stock's beta of -0.11 means it does not correlate with the broader market, offering no diversification benefit and potentially amplifying portfolio risk during sector rotations. Competitive pressures from peers like Lockheed Martin and General Dynamics, plus emerging players in autonomous systems, could erode Northrop's market share. Regulatory risks, including the rare-earth supply chain overhaul mandated by 2027, add another layer of uncertainty. The worst-case scenario involves a combination of a major program charge (e.g., B-21 cost overruns), continued negative free cash flow, and a broader defense budget sequestration. In this scenario, NOC could retest its 52-week low of $470.06, representing a 1.7% decline from the current $478.00, but if analyst bear-case targets of $525 are already above the current price, the true downside may be limited. However, a more severe selloff could push shares to $400, a 16.3% drop, if margins deteriorate below 18% and free cash flow remains negative for multiple quarters.
FAQ
The most severe risk is financial: NOC's debt-to-equity of 1.18x and current ratio of 1.09 leave little room for error, and Q1 2026 free cash flow was negative. Margin compression is a close second, with gross margin falling to 19.5% from 21.4% year-over-year, threatening profitability. Competitive and program-specific risks include the B-21's transition to low-rate production, which could bring cost overruns, and reliance on Chinese rare-earth magnets that may disrupt supply chains. Macro risks are also present: the negative beta of -0.11 means the stock does not benefit from market rallies and may not hedge downturns. Finally, regulatory risks such as defense budget sequestration or continuing resolutions could delay awards and pressure revenue.
The 12-month forecast is based on three scenarios. The base case (55% probability) targets $550-$650, assuming steady revenue growth and stable margins, aligning with the analyst average target of $639.23. The bull case (25% probability) targets $700-$815, driven by successful B-21 execution and geopolitical tailwinds, reaching the analyst high target of $815. The bear case (20% probability) targets $450-$525, assuming program charges and continued negative free cash flow, with a retest of the 52-week low at $470.06. The most likely scenario is the base case, which assumes no major surprises and gradual improvement in cash flow. The key assumption is that gross margin stabilizes above 19.5% and free cash flow turns positive in the second half of 2026.
NOC appears undervalued on a forward earnings basis. The forward PE of 15.70x is significantly below the trailing PE of 19.57x, indicating the market expects earnings growth. The PEG ratio of 7.41 is elevated, suggesting the stock is not cheap relative to its growth rate, but this metric may be distorted by near-term margin pressures. Compared to peers in the aerospace and defense sector, which often trade at 18-22x forward earnings, NOC's multiple is at a discount. The price-to-sales ratio of 1.95 and EV/EBITDA of 13.49 are also reasonable. The market is pricing in low growth expectations, so any positive surprise on margins or cash flow could lead to multiple expansion. Overall, the valuation implies the market is skeptical of the company's ability to convert its backlog into profitable growth.
From a risk/reward perspective, NOC is a moderate buy for value-oriented investors with a long time horizon. The stock trades at $478, implying 33.7% upside to the analyst average target of $639.23, and the forward PE of 15.7x is well below the market average. However, the biggest downside risk is a retest of the 52-week low at $470.06, which is only 1.7% below the current price, suggesting limited immediate downside. The company's negative free cash flow and margin compression are concerns, but the 25.1% ROE and 1.58% dividend yield provide some support. For investors willing to wait 12-18 months for program execution to improve, NOC offers a favorable risk/reward. It is less suitable for short-term traders due to the negative beta and lack of near-term catalysts.
NOC is best suited for long-term investment, with a suggested minimum holding period of 18-24 months. The company is in a transitional phase as the B-21 moves to low-rate production, and the benefits of the $95B+ backlog will take time to materialize in cash flow. The negative beta of -0.11 makes it a poor short-term trading vehicle, as it does not move with the market and can be volatile on company-specific news. The 1.58% dividend yield and 30.9% payout ratio provide income for patient investors. Earnings visibility is high due to long-cycle defense contracts, but near-term quarterly results may be lumpy. Short-term traders should avoid NOC until free cash flow turns positive and margins stabilize, as the stock could remain range-bound between $470 and $550 for several quarters.
